RxDoctor Payments DataLook up a doctor →

Panayotis Ledakis, MD

Hematology & Oncology · Baltimore, MDNPI 1649385634

Payments from drug & device makers

$675,102in general payments, 2019–2025

Across 200 payments — averaging $3375.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$617K
  • Takeda Pharmaceuticals U.S.A., Inc.$43K
  • Immunogen, Inc.$8K
  • Rigel Pharmaceuticals, Inc.$3K
  • AbbVie$459
  • E.r. Squibb & Sons, L.L.C.$409
  • plus $3K from 35 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$675,102 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$4,759,276
Medicare patients
1,099
Services billed
294,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →